loading...| Preferred Name |
Amifostine |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C488 |
| Accepted_Therapeutic_Use_For |
Cisplatin-induced nephrotoxicity; Radiation-induced mucositis and xerostomia |
| CAS_Registry |
112901-68-5 |
| Chemical_Formula |
C5H15N2O3PS.3H2O |
| code |
C488 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. |
| Display_Name |
Amifostine |
| FDA_UNII_Code |
M487QF2F4V |
| FULL_SYN |
Aminopropylaminoethylthiophosphoric Acid Trihydrate Amifostine Trihydrate Ethyol WR2721 Gammaphos 2-[(3-Aminopropyl)amino]ethanethiol Dihydrogen Phosphate Ester Trihydrate S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid Trihydrate WR-2721 APAETP Ethiofos YM-08310 S-2-(3-Aminopropylamino)ethylphosphorothioic Acid Trihydrate WR 2721 Cytofos |
| label |
Amifostine |
| Legacy_Concept_Name |
Amifostine |
| NSC_Code |
296961 |
| PDQ_Closed_Trial_Search_ID |
39741 |
| PDQ_Open_Trial_Search_ID |
39741 |
| Preferred_Name |
Amifostine |
| prefixIRI |
C488 |
| prefLabel |
Amifostine |
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
| UMLS_CUI |
C0591467 |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| http://purl.obolibrary.org/obo/CHEBI_2636 | Chemical Entities of Biological Interest Ontology | LOOM | |
| http://purl.bioontology.org/ontology/MESH/D004999 | Medical Subject Headings | LOOM |